Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Major depression is one of the most prevalent forms of mental illnesses and is among the leading causes of disability, affecting about 121 million people worldwide. Approximately 30% of patients fail to respond to present therapies. Therefore, the search for novel antidepressant drugs continues. AREAS COVERED: The most prescribed antidepressants are serotonin reuptake inhibitors and/or noradrenaline reuptake inhibitors, which only indirectly affect dopaminergic neurotransmission. As a consequence, residual symptoms remain, including impaired motivation and impaired pleasure. This article reviews the development of new broad-spectrum antidepressants, the triple reuptake inhibitors, which also increase brain dopamine levels. EXPERT OPINION: In this review, a distinction is made between the subtypes of melancholic and atypical depressions and their associated brain abnormalities and dysfunctions in neurotransmitter systems. Subsequently, we propose a hypothetical model: 'the monoamine hypothesis revisited' to predict what kind of pharmacological treatment will be effective in the different subtypes of depression. It is expected that the triple reuptake inhibitors, inhibiting the reuptake of all three monoamines, can produce a greater efficacy than traditional antidepressants especially in atypical depression. Since triple reuptake inhibitors may also dampen states of hyperglutamatergic activity and subsequent excitotoxicity, it is suggested that these new drugs have a considerable neuroprotective potential in major depression, especially in melancholic depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Neural systems of reinforcement for drug addiction: from actions to habits to compulsion
Everitt, B. J., & Robbins, T. W. (2005) · Nature Neuroscience · doi:10.1038/nn1579 · Cited by 3,785
Neurons containing hypocretin (orexin) project to multiple neuronal systems
Peyron, C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., & Kilduff, T. S. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-23-09996.1998 · Cited by 3,466 · cited 1×
“Orexin/hypocretin [50] and melaninconcentrating hormone [51] also join this projection.”
BackgroundAntiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149 · cited 1×
“GCs are part of the feedback mechanism in the immune system as well [39].”
BackgroundmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“Remarkably, recently it has been demonstrated that the NMDAreceptor antagonist ketamine rapidly activates themammalian target of rapamycin (mTOR) pathway, leading to increased synaptic signaling proteins and increased number and function of new spine synapses in the PFC of rats [167].”
BackgroundSubgenual prefrontal cortex abnormalities in mood disorders
Drevets, W. C., Price, J. L., Simpson, J. R., Todd, R. D., Reich, T., Vannier, M., & Raichle, M. E. (1997) · Nature · doi:10.1038/386824a0 · Cited by 2,693 · cited 1×
“Therefore, to fully understand the pathophysiology of major depression, one has to measure stress- and depression-related changes in in vivo neurotransmitter reuptake or release; (hetero) receptor trafficking, expression and functioning; post-receptor signaling cascades, gene transcription, translation and expression…”
BackgroundBerridge, C. W., & Waterhouse, B. D. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00143-7 · Cited by 2,529 · cited 1×
“Moreover, the cingulate cortex and PFC are inhibited by noradrenergic fibers from the locus coeruleus (LC) [13,30,31].”
BackgroundKirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Mayberg, H. S., Liotti, M., Brannan, S. K., McGinnis, S., Mahurin, R. K., Jerabek, P. A., Silva, J. A., Tekell, J. L., Martin, C. C., Lancaster, J. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.675 · Cited by 2,416
The mesolimbic dopamine reward circuit in depression
Nestler, E. J., & Carlezon, W. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.018 · Cited by 2,059
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Willner, P., Towell, A., Sampson, D., Sophokleous, S., & Muscat, R. (1987) · Psychopharmacology · doi:10.1007/bf00187257 · Cited by 1,993 · cited 1×
“Reward-related deficits can in turn be measured with an intracranial self-simulation (ICSS) paradigm [200] or the (less sensitive) sucrose preference test [201].”
BackgroundGrace, A. A. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90196-u · Cited by 1,831
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795 · cited 1×
“Therefore, to fully understand the pathophysiology of major depression, one has to measure stress- and depression-related changes in in vivo neurotransmitter reuptake or release; (hetero) receptor trafficking, expression and functioning; post-receptor signaling cascades, gene transcription, translation and expression…”
BackgroundNeurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606 · cited 1×
“Depressed mood has been associated with dysfunctional neuronal activation of the medial prefrontal cortex (mPFC), including the anterior cingulate and orbitofrontal cortex [22-24].”
BackgroundMultiple dopamine functions at different time courses
Schultz, W. (2007) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135722 · Cited by 1,415 · cited 2×
“For example, normal neurotransmission can be explained as a balance between tonic levels of extrasynaptic monoamines that are present at steadystate concentrations in the synaptic cleft and phasic monoamine bursts in response to neuronal firing [121,122].”
BackgroundGold, P. W., & Chrousos, G. P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001032 · Cited by 1,274
Neurobiology of suicidal behaviour
Mann, J. J. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1220 · Cited by 1,260
Affective neuroscience of pleasure: reward in humans and animals
Berridge, K. C., & Kringelbach, M. L. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1099-6 · Cited by 1,254
The role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 6×
“This area is thought to be more important to regulate appetite drives and vegetative functions, including sexual functioning [5,13,46].”
BackgroundInfluentialThe cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182 · cited 1×
“Therefore, to fully understand the pathophysiology of major depression, one has to measure stress- and depression-related changes in in vivo neurotransmitter reuptake or release; (hetero) receptor trafficking, expression and functioning; post-receptor signaling cascades, gene transcription, translation and expression…”
BackgroundChronic mild stress-induced anhedonia: A realistic animal model of depression
Willner, P., Muscat, R., & Papp, M. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80194-0 · Cited by 1,160 · cited 1×
“For example, anhedonia can be induced in animals by exposure to a chronic mild stress paradigm [197], or other stressors, such as social defeat [198] followed by individual housing [199].”
BackgroundStetler, C., & Miller, G. E. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31820ad12b · Cited by 1,123 · cited 1×
“Such a link is the strongest among older inpatients who display melancholic depression (including psychotic features) [81].”
BackgroundSaper, C. B., Chou, T. C., & Elmquist, J. K. (2002) · Neuron · doi:10.1016/s0896-6273(02)00969-8 · Cited by 1,120
Floresco, S. B., West, A. R., Ash, B., Moore, H., & Grace, A. A. (2003) · Nature Neuroscience · doi:10.1038/nn1103 · Cited by 1,106
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 1×
“The rationale for developing a TRI came from indications that augmentation of antidepressant therapy with either the noradrenaline dopamine reuptake inhibitor (NDRI), bupropion [173,174], or the DA receptor agonists [116,117] was clinically effective.”
BackgroundThe Neuropsychopharmacology of Fronto-Executive Function: Monoaminergic Modulation
Robbins, T. W., & Arnsten, A. F. T. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135535 · Cited by 957
Koenigs, M., & Grafman, J. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.03.004 · Cited by 956 · cited 1×
“The PFC is involved in overall cognitive functioning that allows an organism to get things done; problem solving and time planning, reinforcement, reappraisal and suppression of negative affect [25-27].”
BackgroundPharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785
A common neurobiology for pain and pleasure
Leknes, S., & Tracey, I. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2333 · Cited by 784 · cited 1×
“For example, when tonic DA levels are high, the phasic DA response will be attenuated [122,123], whereas low tonic DA facilitates phasic DA postsynaptic functioning [124,125].”
BackgroundThe possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death
Sapolsky, R. M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00971-9 · Cited by 699 · cited 2×
“Chronic exposure to glucocorticosteroids may even cause a selective loss of hippocampal volume and neuron loss [227].”
BackgroundDopamine signals for reward value and risk: basic and recent data
Schultz, W. (2010) · Behavioral and Brain Functions · doi:10.1186/1744-9081-6-24 · Cited by 653
Corticosteroids in relation to fear, anxiety and psychopathology
Korte, S. M. (2001) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(01)00002-1 · Cited by 607 · cited 12×
“However, doubts have risen about this interpretation of the FST [186].”
BackgroundInfluentialSelf-citationPathophysiology of depression: do we have any solid evidence of interest to clinicians?
HASLER, G. (2010) · World Psychiatry · doi:10.1002/j.2051-5545.2010.tb00298.x · Cited by 604 · cited 1×
“Here it must be mentioned that altered glutamatergic and GABA-ergic neurotransmission are, at least partly, responsible for these altered hippocampal and PFC functioning [189].”
BackgroundGlutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments
Krystal, J. H., Sanacora, G., Blumberg, H., Anand, A., Charney, D. S., Marek, G., Epperson, C. N., Goddard, A., & Mason, G. F. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001021 · Cited by 553
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 1×
“There is apparently no clear causal relationship between binding, occupancy and efficacy, because in patients not responding to SSRIs, a comparable transporter occupancy is achieved as in patients responding to treatment [178].”
BackgroundAcute stress enhances glutamatergic transmission in prefrontal cortex and facilitates working memory
Yuen, E. Y., Liu, W., Karatsoreos, I. N., Feng, J., McEwen, B. S., & Yan, Z. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906791106 · Cited by 481 · cited 1×
“Moreover, it has been shown that acute stress may rapidly increase the level of circulating corticosteroids that, by binding to membrane-located mineralocorticoid receptors and rapid non-transcriptional action, induces the release of glutamate in hippocampus [232,233] and, by binding to GRs, induces the release of glu…”
BackgroundPatterns of symptomatic recovery in psychotherapy.
Kopta, S. M., Howard, K. I., Lowry, J. L., & Beutler, L. E. (1994) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.62.5.1009 · Cited by 442 · cited 1×
“These symptoms appear more difficult to treat and respond more slowly to the existing therapy [94-97].”
BackgroundNeural and behavioral substrates of mood and mood regulation
Davidson, R. J., Lewis, D. A., Alloy, L. B., Amaral, D. G., Bush, G., Cohen, J. D., Drevets, W. C., Farah, M. J., Kagan, J., McClelland, J. L., et al. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01458-0 · Cited by 411 · cited 1×
“Depressed mood has been associated with dysfunctional neuronal activation of the medial prefrontal cortex (mPFC), including the anterior cingulate and orbitofrontal cortex [22-24].”
BackgroundMcEwen, B. S., Chattarji, S., Diamond, D. M., Jay, T. M., Reagan, L. P., Svenningsson, P., & Fuchs, E. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.80 · Cited by 406 · cited 1×
“Special attention should be given to the main excitatory and inhibitory neurotransmitters, respectively glutamate and GABA, that are involved in the pathophysiology of major depression [126-137].”
BackgroundSequeira, A., Mamdani, F., Ernst, C., Vawter, M. P., Bunney, W. E., Lebel, V., Rehal, S., Klempan, T., Gratton, A., Benkelfat, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006585 · Cited by 388 · cited 1×
“Recently, it was shown that the cingulate and/or PFC displayed upregulation of several glutamate and GABAA receptor subunits, of which GABAAa1, a3, a4, d and GABAAb3 expressions were changed in individuals who had died by suicide [131,138,139].”
BackgroundGlucocortcoids mediate the stress-induced extracellular accumulation of glutamate
Moghaddam, B., Bolinao, M. L., Stein-Behrens, B., & Sapolsky, R. (1994) · Brain Research · doi:10.1016/0006-8993(94)91622-5 · Cited by 378
Nutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., Carrasco, J. L., & Stahl, S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106069938 · Cited by 366
Tremblay, L. K., Naranjo, C. A., Graham, S. J., Herrmann, N., Mayberg, H. S., Hevenor, S., & Busto, U. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1228 · Cited by 340
Sun, X., Zhao, Y., & Wolf, M. E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4603-04.2005 · Cited by 299 · cited 1×
“Stimulation of D1 dopamine receptors increases surface expression of GluR1-containing AMPA receptors through a PKA-dependent mechanism, thereby creating a receptor pool available for synaptic insertion [172].”
BackgroundThe many faces of fatigue in major depressive disorder
Demyttenaere, K., De Fruyt, J., & Stahl, S. M. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004729 · Cited by 288 · cited 1×
“These symptoms appear more difficult to treat and respond more slowly to the existing therapy [94-97].”
BackgroundHorn (2010) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2010.00033 · Cited by 276
Lamers, F., de Jonge, P., Nolen, W. A., Smit, J. H., Zitman, F. G., Beekman, A. T. F., & Penninx, B. W. J. H. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05398blu · Cited by 264 · cited 5×
“Disturbances in these projections might lead to an altered sleep--wake cycle, which will result in insomnia in melancholic depression and excessive sleep and hypersomnia in atypical depression [12,13].”
BackgroundMethodInfluentialKatz, M. M., Tekell, J. L., Bowden, C. L., Brannan, S., Houston, J. P., Berman, N., & Frazer, A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300341 · Cited by 252 · cited 1×
“The same distinction can be made in humans, where drug-induced alterations in the serotonergic system have been associated with anxiolytic effects and changes in the noradrenergic systems with reducing psychomotor symptoms [184].”
BackgroundEntsuah, A. R., Huang, H., & Thase, M. E. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1106 · Cited by 245
Through the looking glass: Differential noradenergic modulation of prefrontal cortical function
Arnsten, A. F. T. (2000) · Neural Plasticity · doi:10.1155/np.2000.133 · Cited by 229
Tremblay, L. K., Naranjo, C. A., Cardenas, L., Herrmann, N., & Busto, U. E. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.5.409 · Cited by 229
Martinot, M.-L. P., Bragulat, V., Artiges, E., Dollé, F., Hinnen, F., Jouvent, R., & Martinot, J.-L. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.314 · Cited by 194
Cellular and molecular mechanisms in the long-term action of antidepressants.
Racagni, G., & Popoli, M. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/gracagni · Cited by 192 · cited 2×
“This combined effect would produce a dampening of glutamate neurotransmission and an enhancement of AMPA- vs NMDA-mediated neurotransmission and thereby would increase neuroplasticity, cellular resilience and synaptic plasticity [148].”
BackgroundMolecular mechanisms of neuroplasticity and pharmacological implications: the example of tianeptine
McEwen, B. S., & Chattarji, S. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.09.008 · Cited by 174
Using epidemiological data to model efficiency in reducing the burden of depression
Andrews, G., Sanderson, K., Corry, J., & Lapsley, H. M. (2000) · The Journal of Mental Health Policy and Economics · doi:10.1002/mhp.96 · Cited by 110 · cited 1×
“Major depressive disorder (MDD) is one of the most prevalent forms of mental illnesses and is among the leading causes of disability, affecting about 121 million people worldwide [1].”
BackgroundPapakostas, G. I., Nelson, J. C., Kasper, S., & Möller, H.-J. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.07.005 · Cited by 73 · cited 1×
“Where fluoxetinetreated patients are more likely to experience nausea, hypersomnia and fatigue, reboxetine-treated patients experienced more constipation, painful urination (dysuria) and insomnia [103].”
BackgroundRopinirole in treatment-resistant depression: a 16-week pilot study
Cassano, P., Lattanzi, L., Fava, M., Navari, S., Battistini, G., Abelli, M., & Cassano, G. B. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505000612 · Cited by 73
Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex
Tokarski, K., Bobula, B., Wabno, J., & Hess, G. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.03.007 · Cited by 65
Cited by
Kopschina Feltes, P., Doorduin, J., Klein, H. C., Juárez-Orozco, L. E., Dierckx, R. A., Moriguchi-Jeckel, C. M., & de Vries, E. F. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117711708 · Cited by 279
“It suggests that an imbalance, mainly in serotonergic and noradrenergic neurotransmission is the core of the pathophysiology of depression (Massart et al., 2012; Prins et al., 2011).”
BackgroundSerotonergic Drugs for Depression and Beyond
M. Stahl, S., Lee-Zimmerman, C., Cartwright, S., & Ann Morrissette, D. (2013) · Current Drug Targets · doi:10.2174/1389450111314050007 · Cited by 272
Serotonin: A never-ending story
Olivier, B. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.031 · Cited by 253
Self-citationHomer1/mGluR5 Activity Moderates Vulnerability to Chronic Social Stress
Wagner, K. V., Hartmann, J., Labermaier, C., Häusl, A. S., Zhao, G., Harbich, D., Schmid, B., Wang, X.-D., Santarelli, S., Kohl, C., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.308 · Cited by 67
Newton, D. F., Oh, H., Shukla, R., Misquitta, K., Fee, C., Banasr, M., & Sibille, E. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.10.015 · Cited by 19
Metadata
- Authors
- Prins, J., Olivier, B., & Korte, S. M.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2011-06-20
- Volume
- 20
- Issue
- 8
- Pages
- 1107-1130
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2029145502
- Cited by
- 97
- References
- 62
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.